Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 6/20 | 0.70 |
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.70 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.70 |
| ▸ | NMBR | P28336 | 2/20 | 0.70 |
| ▸ | REN | P00797 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | CTSK | P43235 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052771 | 0.94 | NMBR (0.71) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL12052806 | 0.94 | NMBR (0.71) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL14595064 | 0.93 | NMBR (0.74) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL5380441 | 0.93 | NMBR (0.74) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL11981434 | 0.92 | NMBR (0.69) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL8019332 | 0.92 | NMBR (0.71) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL7275505 | 0.92 | NMBR (0.74) | IL1RNERAP2ERAP1NMBRREN | |
| SCHEMBL16617130 | 0.92 | NMBR (0.71) | NMBRRENMAPTLMNAGAA | |
| SCHEMBL11765479 | 0.92 | NMBR (0.71) | NMBRRENMAPTLMNAGAA | |
| SCHEMBL5380023 | 0.92 | NMBR (0.71) | NMBRRENMAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | IL1RN 887/4885ERAP2 64/4885ERAP1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.